Identification of polymorphisms associated with hypertriglyceridemia and prolonged survival induced by bexarotene in treating non-small cell lung cancer

Anticancer Research

Volumn 31, Issue 6, 2011, Pages 2303-2311

  Luo, Wen ^a   Schork, Nicholas J ^b   Marschke, Keith B ^a   Ng, Shi Chung ^a   Hermann, Thomas W ^a   Zhang, Jinkun ^a   Sanders, Jennifer M ^a   Tooker, Patricia ^a   Malo, Nathalie ^b   Zapala, Matthew A ^b   Dziewanowska, Zofia E ^a   Negro Vilar, Andres ^a   Meglasson, Martin D ^a  

^a LIGAND PHARMACEUTICALS INC   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Bexarotene; Lung cancer; Pharmacogenomics; RXR; SNPs

Indexed keywords

BEXAROTENE; CARRIER PROTEINS AND BINDING PROTEINS; DNA; LYMPHOCYTE CYTOSOLIC PROTEIN 1; SOLUTE CARRIER FAMILY 10 MEMBER 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER CELL; CANCER SURVIVAL; DISEASE ASSOCIATION; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYPERTRIGLYCERIDEMIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CLINICAL TRIALS, PHASE III AS TOPIC; DNA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTRIGLYCERIDEMIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TETRAHYDRONAPHTHALENES;

EID: 79960440224     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Boehm MF, Zhang L, Badea B-A, White SK, Mais DE, Berger EM, Suto CM, Goldman ME and Heyman RA: Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J of Med Chem 37: 2930-2941, 1994. (Pubitemid 24297810)
2. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C and Yocum RC: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19: 2456-2471, 2001. (Pubitemid 32391217)
3. Khuri FR, Rigas JR, Figlin RA, Gralla RJ, Shin DM, Munden R, Fox N, Huyghe MR, Kean Y, Reich SD and Hong WK: Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small cell lung cancer. J Clin Oncol 19: 2626-2637, 2001. (Pubitemid 32441367)
4. Edelman MJ, Smith R, Hausner P, Doyle LA, Kalra K, Kendall J, Bedor M and Bisaccia S: Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol 23: 5774-5778, 2005.
5. Yen W-C and Lamph WW: The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol Cancer Thera 4: 824-834, 2005. (Pubitemid 40767127)
6. Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, Lamph WW, Kuhn JG, Green JE and Brown PH: Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev 11: 467-474, 2002. (Pubitemid 34517942)
7. Rizvi NA, Marshall JL, Dahut W, Ness E, Truglia JA, Loewen G, Gill GM, Ulm EH, Geiser R, Jaunakais D and Hawkins MJ: A Phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res 5: 1658-1664, 1999. (Pubitemid 29334442)
8. Miller VA, Benedetti FM, Rigas JR, Verret AL, Pfister DG, Straus D, Kris MG, Crisp M, Heyman R, Loewen GR, Truglia JA and Warrell RP Jr.: Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 15: 790-795, 1997.
9. Ramlau R, Zatloukal P, Jassem J, Schwarzenberger P, Orlov SV, Gottfried M, Pereira JR, Temperley G, Negro-Vilar R, Rahal S, Zhang JK, Negro-Vilar A and Dziewanowska ZE: Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/ vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. J Clin Oncol 26: 1886-1892, 2008.
10. Blumenschein GR Jr., Khuri FR, von Pawel J, Gatzemeier U, Miller WH Jr., Jotte RM, Le Treut J, Sun SL, Zhang JK, Dziewanowska ZE and Negro-Vilar A: Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J Clin Oncol 26: 1879-1885, 2008.
11. Govindan R, Crowley J, Schwartzberg L, Kennedy P, Williams C, Ekstrand B, Sandler A, Jaunakais D, Bolejack V and Ghalie R: Phase II Trial of Bexarotene Capsules in Patients With Advanced Non-Small-Cell Lung Cancer After Failure of Two or More Previous Therapies. J Clin Oncol 24: 4848-4854, 2006. (Pubitemid 46630911)
12. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ and Sham PC: PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575, 2007.
13. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR and Gronemeyer H: RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 6: 793-810, 2007. (Pubitemid 47504871)
14. Pinaire JA and Reifel-Miller A: Therapeutic potential of retinoid x receptor modulators for the treatment of the metabolic syndrome. PPAR Res 2007: 94156, 2007.
15. Chiang JY: Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev 23: 443-463, 2002.
16. Kast HR, Nguyen CM, Sinai CJ, Jones SA, Laffitte BA, Reue K, Gonzalez FJ, Willson TM and Edwards PA: Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol 15: 1720-1728, 2001. (Pubitemid 32939302)
17. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, Moore DD and Auwerx J: Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 113: 1408-1418, 2004. (Pubitemid 39071696)
18. Carulli N, Ponz de Leon M, Podda M, Zuin M, Strata A, Frigerio G and Digrisolo A: Chenodeoxycholic acid and ursodeoxycholic acid effects in endogenous hypertriglyceridemias. A controlled double-blind trial. J Clin Pharmacol 21: 436-442, 1981. (Pubitemid 12196438)
19. Duane WC, Hartich LA, Bartman AE and Ho SB: Diminished gene expression of ileal apical sodium bile acid transporter explains impaired absorption of bile acid in patients with hypertriglyceridemia. J Lipid Res 41: 1384-1389, 2000.
20. Love MW, Craddock AL, Angelin B, Brunzell JD, Duane WC and Dawson PA: Analysis of the ileal bile acid transporter gene, SLC10A2, in subjects with familial hypertriglyceridemia. Arterioscler Thromb Vasc Biol 21: 2039-2045, 2001. (Pubitemid 34219759)
21. Jung D, Fried M and Kullak-Ublick GA: Human apical sodium-dependent bile salt transporter gene (SLC10A2) is regulated by the peroxisome proliferator-activated receptor alpha. J Biol Chem 277: 30559-30566, 2002. (Pubitemid 34970749)
22. Neimark E, Chen F, Li X and Shneider BL: Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatology 40: 149-156, 2004. (Pubitemid 38877576)
23. Delanote V, Vandekerckhove J and Gettemans J: Plastins: versatile modulators of actin organization in (patho)physiological cellular processes. Acta Pharmacol Sin 26: 769-779, 2005. (Pubitemid 40978757)
24. Samstag Y and Klemke M: Ectopic expression of L-plastin in human tumor cells: diagnostic and therapeutic implications. Adv Enzyme Regul 47: 118-126, 2007. (Pubitemid 47302064)
25. Prislei S, Mozzetti S, Filippetti F, De Donato M, Raspaglio G, Cicchillitti L, Scambia G and Ferlini C: From plasma membrane to cytoskeleton: a novel function for semaphorin 6A. Mol Cancer Ther 7: 233-241, 2008.
26. Gan PP, Pasquier E and Kavallaris M: Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 67: 9356-9363, 2007. (Pubitemid 47535925)
27. Verrills NM, Po'uha ST, Liu ML, Liaw TY, Larsen MR, Ivery MT, Marshall GM, Gunning PW and Kavallaris M: Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia. J Natl Cancer Inst 98: 1363-1374, 2006.
28. Lu Y, Gioia-Patricola L, Gomez JV, Plummer M, Franceschi S, Kato I and Canzian F: Use of whole genome amplification to rescue DNA from plasma samples. Biotechniques 39: 511-515, 2005.
29. Park JW, Beaty TH, Boyce P, Scott AF and Mcintosh I: Comparing whole-genome amplification methods and sources of biological samples for single-nucleotide polymorphism genotyping. Clin Chem 51: 1520-1523, 2005. (Pubitemid 41060891)